NCT06736132

Brief Summary

High-flow nasal oxygen (HFNO) has been used for many years to help people with breathing difficulties in the intensive care and after surgery. More recently, it has become a helpful tool during induction of anaesthesia to prevent oxygen levels from dropping when managing the airway. HFNO is particularly effective at delivering oxygen even when a patient is not breathing (apnoea), making it useful during surgeries on the voice box (larynx) because it eliminates the need for a breathing tube, giving surgeons a clear view. HFNO is now also being used to prepare patients for anaesthesia (preoxygenation). Research shows that it works just as well as traditional tight-fitting oxygen masks while offering added benefits like better comfort for patients, easier handling for anaesthetists, and a smooth transition to oxygen delivery during apnoea. One reason HFNO is effective is that it creates a mild pressure in the lungs, called positive end-expiratory pressure (PEEP), which improves oxygen storage in the lungs. This pressure depends on the flow rate of oxygen and is higher when the patient keeps their mouth closed. For every increase of 10 liters per minute in flow rate, HFNO generates 1 cmH2O of PEEP. This pressure helps increase the lung's capacity to hold oxygen, making the process of preoxygenation more efficient. Most studies on HFNO for preoxygenation have used flow rates of up to 60 liters per minute. However, we don't yet know if higher flow rates could further improve preoxygenation or extend the time patients can safely go without breathing.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
75

participants targeted

Target at P50-P75 for not_applicable

Timeline
7mo left

Started Jan 2025

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress70%
Jan 2025Dec 2026

First Submitted

Initial submission to the registry

December 9, 2024

Completed
7 days until next milestone

First Posted

Study publicly available on registry

December 16, 2024

Completed
28 days until next milestone

Study Start

First participant enrolled

January 13, 2025

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2026

Expected
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2026

Last Updated

June 27, 2025

Status Verified

December 1, 2024

Enrollment Period

1.4 years

First QC Date

December 9, 2024

Last Update Submit

June 23, 2025

Conditions

Keywords

PreoxygenationHigh-flow nasal oxygenAnaesthesia induction

Outcome Measures

Primary Outcomes (1)

  • Safe apnoea time

    Comparison of the time from start of apnoea until reaching a SpO2 = 93% between the different flow rates

    From start of apnoea after anaesthesia induction until peripheral oxygen saturation drops to 93%. This time fram will probably be between 5 and 15 minutes.

Secondary Outcomes (4)

  • Tolerance of 360 seconds of apnoea

    From apnoea start until 5 minutes of apnoea

  • Arterial oxygen levels during preoxygenation

    From start of preoxygenation until end of preoxygenation (approximately 3 to 4 minutes)

  • Discomfort assessment

    From start of preoxygenation until the end of preoxygenation, this time fram will be three minutes.

  • Lung impedance changes

    From start of preoxygenation until end of apnoea (approximately 5 to 15 minutes)

Other Outcomes (2)

  • Differences in end-tidal and arterial carbon dioxide levels

    From start of apnoea until end of apnoea (approximately 5 to 10 minutes)

  • Rate of arterial carbon dioxide increase during apnoea

    From start of apnoea until end of apnoea (approximately 5 to 10 minutes)

Study Arms (3)

High-flow nasal oxygen, flow rate 45 l/min

ACTIVE COMPARATOR

Preoxygenation using high-flow nasal oxygen with a flow rate of 45 l/min

Device: High-flow nasal oxygen

High-flow nasal oxygen, flow rate 70 l/min

EXPERIMENTAL

Preoxygenation using high-flow nasal oxygen with a flow rate of 70 l/min

Device: High-flow nasal oxygen

High-flow nasal oxygen, flow rate 95 l/min

EXPERIMENTAL

Preoxygenation using high-flow nasal oxygen with a flow rate of 95 l/min

Device: High-flow nasal oxygen

Interventions

In this study, we will use high-flow nasal oxygen for preoxygenation in patients undergoing elective anaesthesia. Preoxygenation with high-flow nasal oxygen is most often performed at flow rates of \<50 l/min. In this study, patients will be randomised to preoxygenation using high-flow nasal oxygen and flow rates of 45 l/min, 70 l/min or 95 /min.

High-flow nasal oxygen, flow rate 45 l/minHigh-flow nasal oxygen, flow rate 70 l/minHigh-flow nasal oxygen, flow rate 95 l/min

Eligibility Criteria

Age18 Years - 84 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adult, 18-84 years old
  • ASA 1-3
  • BMI \< 35
  • Planned for elective surgery

You may not qualify if:

  • Cardiac disease (ischemic heart disease, heart failure (NYHA ≥2), ongoing arrhythmias, pulmonary hypertension)
  • Severe asthma, moderate to severe COPD
  • Pregnancy
  • Baseline oxygen saturation \< 95%
  • Nasal obstruction
  • Known or anticipated difficult airway
  • Patients with electrical active implants where lung impedance analysis is contraindicated
  • Not capable of understanding study information and signing a written consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Karolinska University Hospital

Solna, 17176, Sweden

Location

Related Publications (1)

  • Sjoblom A, Hoffman F, Hedberg M, Forsberg IM, Jonsson Fagerlund M. Preoxygenation with high-flow nasal oxygen at various flow rates in elective surgical patients: a prospective, randomised, single-blind clinical trial. Br J Anaesth. 2025 Dec 18:S0007-0912(25)00816-5. doi: 10.1016/j.bja.2025.11.017. Online ahead of print.

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, CARE PROVIDER
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Randomised controlled trial
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

December 9, 2024

First Posted

December 16, 2024

Study Start

January 13, 2025

Primary Completion (Estimated)

June 1, 2026

Study Completion (Estimated)

December 1, 2026

Last Updated

June 27, 2025

Record last verified: 2024-12

Data Sharing

IPD Sharing
Will not share

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available because they contain information that could compromise the privacy of research participants.

Locations